Pliant Therapeutics Q1 EPS $(0.78) Misses $(0.77) Estimate
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics reported Q1 EPS of $(0.78), missing the consensus estimate of $(0.77) by 1.3%, marking a 16.42% increase in losses from the same period last year.
May 06, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pliant Therapeutics reported a larger than expected quarterly loss, missing analyst estimates.
Missing the EPS estimate, even by a small margin, can negatively impact investor sentiment and stock price in the short term. The reported increase in losses compared to the previous year further exacerbates this effect, suggesting a negative short-term impact on PLRX's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100